Background: The objective of this research was to investigate the possibility of predicting the retention or discontinuation of contact lenses on the basis of their effect on the quality of life of the wearer. While most studies of discontinuation of assistive technology devices have focused on other than psychosocial causes of discontinuation, there is reason to believe that a major cause is the psychosocial effect of the device on the user.
Methods: Participants were 418 adult volunteers who had been fitted with contact lenses. One hundred eighty of the participants had discontinued wearing their lenses, while 238 were still wearing their lenses. The participants were asked to complete a recently developed questionnaire, the Psychosocial Impact of Assistive Devices Scales (PIADS), which measures the psychosocial impact of assistive devices, and is used also to predict retention and discontinuation of other assistive devices.
Results: Overall correct prediction of the 418 respondents was 68.9%. The PIADS was better at predicting discontinuation than retention among males, while the reverse was true for females.
Conclusions: The PIADS was shown to be a valid instrument to predict retention and discontinuation of contact lenses.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and tolerability of lacosamide in pediatric and young adult epilepsy patients with severe motor and intellectual disabilities.
Neuropediatrics
December 2024
Pediatrics, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Objective: Epilepsy is common among patients with severe motor and intellectual disability (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures.
View Article and Find Full Text PDFEffects of prolonged oxytetracycline supplementation on freshwater stinging catfish (): a multi-biomarker approach.
Front Immunol
January 2025
Indian Council of Agriculture Research (ICAR)-Central Institute of Freshwater Aquaculture (CIFA), Fish Health Management Division, Bhubaneswar, Odisha, India.
Background: Aquaculture systems that sporadically depend on antibiotics can contribute to the development of adverse effects on the fish, microbial flora and the environment. This study sought to investigate the impacts of extended oxytetracycline supplementation on the freshwater stinging catfish through a multi-biomarker approach.
Methods: A total of 300 (20 ± 0.
Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR.
Trials
January 2025
Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Background: There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment; however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches.
View Article and Find Full Text PDFPersistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.
J Pharm Technol
December 2024
Rheumatology Department, Hospital de Sagunto, Port de Sagunt, Spain.
Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment.
View Article and Find Full Text PDFPrescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.
Nat Ment Health
July 2024
Department of Family/Community Medicine and Health and Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA.
While attention deficit hyperactivity disorder is common among people with addiction, the risks and benefits of attention deficit hyperactivity disorder medication in pregnant people with opioid use disorder are poorly understood. Here, using US multistate administrative data, we examined 3,247 pregnant people initiating opioid use disorder treatment, of whom 5% received psychostimulants. Compared to peers not receiving psychostimulants, the psychostimulant cohort had greater buprenorphine (adjusted relative risk 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!